NIKKEI 225
28,267.93 +340.56 (+1.22%) HANG SENG
23,540.88 +191.50 (+0.82%) CRUDE OIL
70.10 +0.61 (+0.88%) GOLD FUTURES
1,780.60 +1.10 (+0.06%) DOW
35,227.03 +646.95 (+1.87%) BTC-GBP
38,343.30 +1,180.84 (+3.18%)
LONZA GROUP AG LONZA GROUP ORD (0QNO.IL)
| Previous close | 402.20 |
| Open | 401.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 396.40 - 404.10 |
| 52-week range | 396.40 - 785.40 |
| Volume | |
| Avg. volume | 759 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth
Lonza Group AG / Key word(s): Conference/Forecast12-Oct-2021 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad Hoc News Release Pursuant to Art. 53 Listing Rules At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth 2021 CAPEX a
- EQS Group
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results23-Jul-2021 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaboratio
- EQS Group
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
Lonza Group AG / Key word(s): Agreement/Development of Sales16-Jul-2021 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all ele
